Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Availability of an assay for detecting Mycobacterium tuberculosis, including rifampin-resistant strains, and considerations for its use - United States, 2013.

MMWR. Morbidity and mortality weekly report - 18 Oct 2013

Abstract excerpt

In August 2013, the Food and Drug Administration (FDA) permitted marketing of the Xpert MTB/RIF assay (Cepheid, Sunnyvale, California) to detect DNA of the Mycobacterium tuberculosis complex (MTBC) and genetic mutations associated with resistance to rifampin (RMP) in unprocessed sputum and concentrated sputum sediments. Along with clinical, radiographic, and other laboratory findings, results of the assay aid in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Bacterial
Share to Infection Control
Share to Mycobacterium tuberculosis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Nucleic Acid Amplification Techniques

Share to Practice Guidelines as Topic

Share to Rifampin

Share to Tuberculosis, Pulmonary

Share to United States

Source

Open in PubMed Open full text

Identifiers

PMID: 24141407
PMCID: PMC4585342

Genes

DST

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Availability of an assay for detecting Mycobacterium tuberculosis, including rifampin-resistant strains, and considerations for its use - United States, 2013.PMID 24141407Read ↗

Access the Diagnostic Accuracy of GeneXpert to Detect <em>Mycobacterium tuberculosis</em> and Rifampicin-Resistance Tuberculosis among Presumptive Tuberculosis and Presumptive Drug Resistant Tuberculosis PatientsSemantic proximity Read ↗

Current Landscape of Molecular Diagnostic Tests for Tuberculosis and Drug Resistance: From Routine Practice to Emerging TechnologiesSemantic proximity Read ↗

Multidrug-resistant tuberculosis.Semantic proximity Read ↗

Analytical performance of a multi-target open real-time PCR assay for simultaneous detection of tuberculosis, non-tuberculous mycobacteria, and drug resistance in a high-burden settingSemantic proximity Read ↗

An evaluation of false-positive rifampicin resistance on the Xpert MTB/RIF.Semantic proximity Read ↗

Performance of the G4 Xpert® MTB/RIF assay for the detection of Mycobacterium tuberculosis and rifampin resistance: a retrospective case-control study of analytical and clinical samples from high- and low-tuberculosis prevalence settings.Semantic proximity Read ↗

Performance of an Xpert-based diagnostic algorithm for the rapid detection of drug-resistant tuberculosis among high-risk populations in a low-incidence setting.Semantic proximity Read ↗

Exploring Diagnostic Methods for Drug-Resistant Tuberculosis: A Comprehensive OverviewSemantic proximity Read ↗

Evaluation of a Rapid Molecular Drug-Susceptibility Test for Tuberculosis.Semantic proximity Read ↗

Exploring diagnostic methods for drug-resistant tuberculosis: A comprehensive overview.Semantic proximity Read ↗

The performance of Xpert MTB/RIF and MTBDRplus within a Programmatic setting at TB Laboratory in Rio de Janeiro, Brazil.Semantic proximity Read ↗

Evaluation of the Analytical Performance of the Xpert MTB/RIF AssaySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.